DK1192247T3 - Sphingosinkinaseenzym - Google Patents

Sphingosinkinaseenzym

Info

Publication number
DK1192247T3
DK1192247T3 DK00926537T DK00926537T DK1192247T3 DK 1192247 T3 DK1192247 T3 DK 1192247T3 DK 00926537 T DK00926537 T DK 00926537T DK 00926537 T DK00926537 T DK 00926537T DK 1192247 T3 DK1192247 T3 DK 1192247T3
Authority
DK
Denmark
Prior art keywords
present
mimetics
analogues
derivatives
sphingosine kinase
Prior art date
Application number
DK00926537T
Other languages
English (en)
Inventor
Stuart Maxwell Pitson
Brian Wolff Wattenberg
Pu Xia
Andrea Richard James D
Jennifer Ruth Gamble
Mathew Alexander Vadas
Original Assignee
Johnson & Johnson Pharm Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ0339A external-priority patent/AUPQ033999A0/en
Priority claimed from AUPQ1504A external-priority patent/AUPQ150499A0/en
Application filed by Johnson & Johnson Pharm Res filed Critical Johnson & Johnson Pharm Res
Application granted granted Critical
Publication of DK1192247T3 publication Critical patent/DK1192247T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00926537T 1999-05-13 2000-05-12 Sphingosinkinaseenzym DK1192247T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ0339A AUPQ033999A0 (en) 1999-05-13 1999-05-13 Novel therapeutic molecules and uses thereof
AUPQ1504A AUPQ150499A0 (en) 1999-07-08 1999-07-08 Novel therapeutic molecules and uses thereof-II

Publications (1)

Publication Number Publication Date
DK1192247T3 true DK1192247T3 (da) 2006-07-31

Family

ID=25646054

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00926537T DK1192247T3 (da) 1999-05-13 2000-05-12 Sphingosinkinaseenzym

Country Status (11)

Country Link
US (3) US6730480B1 (da)
EP (1) EP1192247B9 (da)
JP (1) JP2002543831A (da)
KR (1) KR100798375B1 (da)
AT (1) ATE323153T1 (da)
CA (1) CA2372541A1 (da)
DE (1) DE60027295T2 (da)
DK (1) DK1192247T3 (da)
ES (1) ES2261200T3 (da)
NZ (1) NZ515132A (da)
WO (1) WO2000070028A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
BR0015138A (pt) * 1999-10-28 2002-07-16 Warner Lambert Co Gene da esfingosina quinase humana
US6858427B2 (en) * 2000-02-14 2005-02-22 Genentech, Inc. Sphingosine kinases
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
EP1299548A4 (en) * 2000-06-28 2004-12-01 Medvet Science Pty Ltd THERAPEUTIC MOLECULAR VARIANTS AND THEIR USE
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
EP1363643A2 (en) 2000-12-22 2003-11-26 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
CA2449487A1 (en) * 2001-06-07 2002-12-12 Pu Xia Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
WO2003062390A2 (en) * 2002-01-17 2003-07-31 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
AU2003215426A1 (en) * 2002-03-28 2003-10-13 Medvet Science Pty. Ltd. A method of modulating cellular activity
EP1558736A4 (en) * 2002-10-14 2006-05-10 Medvet Science Pty Ltd METHOD FOR MODULATING THE ACTIVITY OF AN EPITHELIAL CELL USING MODULATION OF FUNCTIONAL LEVELS OF SPHINGOSINE KINASE
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
AU2006299417A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
SI2087002T1 (sl) 2006-10-27 2014-11-28 Lpath, Inc. Sestavki in postopki za vezavo sfingozin-1-fosfata
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8778614B2 (en) 2010-08-24 2014-07-15 Enzo Life Sciences, Inc. Assays for detecting modified compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525174B1 (en) * 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
EP1039801A4 (en) * 1997-06-06 2003-03-26 Human Genome Sciences Inc 207 HUMAN SECRETED PROTEINS
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
EP1235913A2 (en) 1998-05-26 2002-09-04 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
GB9816030D0 (en) 1998-07-22 1998-09-23 Smithkline Beecham Plc Novel compounds
WO2000052173A2 (en) * 1999-03-02 2000-09-08 Nps Allelix Corp. Cloned human sphingosine kinase homologues
WO2000055332A2 (en) * 1999-03-18 2000-09-21 Incyte Pharmaceuticals, Inc. Human regulators of intracellular phosphorylation
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

Also Published As

Publication number Publication date
ES2261200T3 (es) 2006-11-16
EP1192247B9 (en) 2007-10-31
KR100798375B1 (ko) 2008-01-28
NZ515132A (en) 2005-01-28
EP1192247B1 (en) 2006-04-12
KR20020000805A (ko) 2002-01-05
US20040132053A1 (en) 2004-07-08
DE60027295T2 (de) 2007-01-18
US7112427B2 (en) 2006-09-26
DE60027295D1 (de) 2006-05-24
JP2002543831A (ja) 2002-12-24
CA2372541A1 (en) 2000-11-23
ATE323153T1 (de) 2006-04-15
US20070071752A1 (en) 2007-03-29
EP1192247A4 (en) 2003-05-28
WO2000070028A1 (en) 2000-11-23
EP1192247A1 (en) 2002-04-03
US6730480B1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
DK1192247T3 (da) Sphingosinkinaseenzym
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EP2679235A3 (en) Peptides and related molecules that modulate nerve growth factor activity
HUP0401124A2 (hu) VII koagulációs faktor származékok
DE69939864D1 (de) Ppar-gamma modulatoren
AU2003266214A1 (en) Human coagulation factor vii polypeptides
TW200407425A (en) Human coagulation factor VII polypeptides
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
AUPP472398A0 (en) Protease susceptibility II
DE60137978D1 (de) Zusammensetzung zur förderung des haarwachstums
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
WO2000053776A3 (en) Human kallikrein-like genes
NO20014537L (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
IL149416A0 (en) Human enzymes of the metalloprotease family
DE60214867D1 (en) Histonedeacetylase 9
DK1339853T3 (da) Isolerede luciferaser og deres anvendelse
DE69535232D1 (de) DNA-SEQUENZEN, DIE FÜR DIE MENSCHLICHE PROTEINE Tx UND Ty KODIEREN, DIE ICE GLEICHEN
WO2002004521A3 (en) Proteins with integrin-like activity
WO2001058954A3 (en) Trade molecules and uses related thereto
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
EP1383871A4 (en) INSULATED HUMAN ENZYMATIC PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE PROTEINS, AND USES THEREOF
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
MXPA02012924A (es) Nuevas variantes moleculares terapeuticas y sus usos.